Amyvid 800 MBq/mL solution for injection, ACU193 matching Placebo, Neuraceq 300 MBq/mL solution for injection, ACU193, VIZAMYL 400 MBq/mL solution for injection
ACU193-201
Phase 2 small_molecule active
Quick answer
Amyvid 800 MBq/mL solution for injection, ACU193 matching Placebo, Neuraceq 300 MBq/mL solution for injection, ACU193, VIZAMYL 400 MBq/mL solution for injection for Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease) is a Phase 2 program (small_molecule) at Acumen Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Acumen Pharmaceuticals
- Indication
- Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active